Aclarion, Inc. is a healthcare technology company that focuses on leveraging advanced imaging and machine learning to enhance the assessment and treatment of chronic pain conditions
By utilizing proprietary algorithms and data analysis techniques, the company aims to improve patient outcomes through more accurate diagnostics and personalized treatment plans. Aclarion seeks to transform the way healthcare providers approach pain management by integrating innovative solutions that combine clinical expertise with cutting-edge technology, ultimately leading to better quality of care for patients suffering from debilitating pain.
Earlier this month, the stock received a boost after the company announced it had terminated an agreement with Ascendiant Capital for a $10 million at-the-market share offering.
After the conclusion of the US market's regular session on Thursday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.
Let's delve into the US markets on Thursday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.
BROOMFIELD, CO - January 30, 2025 (NEWMEDIAWIRE) - Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced that it has agreed to sell 506,803 shares of its common stock at a price per share of $9.25 in a registered direct offering priced at the market. All of the shares of common stock in the offering are being sold by Aclarion. The closing of the offering is expected to take place on or about January 31, 2025, subject to the satisfaction of customary closing conditions.
After the conclusion of the US market's regular session on Tuesday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.
BROOMFIELD, CO - January 28, 2025 (NEWMEDIAWIRE) - Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, today announced revised timing and a revised split ratio for its pending reverse stock split of its common stock.
As the US market prepares to open on Monday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.
Curious about the most active stocks in today's session? Get a glimpse into the stocks that are generating the highest trading volume and capturing market attention.
Wondering how the US markets performed in the middle of the day on Friday? Discover the movers and shakers of today's session in our comprehensive analysis.
BROOMFIELD, CO - January 24, 2025 (NEWMEDIAWIRE) - Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, today announced that effective before market open on Wednesday, January 29, 2025, it will complete a 1-for-370 reverse stock split of its common stock.
